These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 33117020

  • 1. An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study).
    Lissitchkov T, Klukowska A, Buevich E, Maltceva I, Auerswald G, Stasyshyn O, Seifert W, Rogosch T.
    J Blood Med; 2020; 11():345-356. PubMed ID: 33117020
    [Abstract] [Full Text] [Related]

  • 2. Efficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pediatric Patients <12 Years of Age with Hemophilia A (SWIFTLY-HA Study).
    Djambas Khayat C, Iosava G, Romashevskaya I, Stasyshyn O, Lopez MJ, Pompa MT, Rogosch T, Seifert W.
    J Blood Med; 2021; 12():483-495. PubMed ID: 34188580
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study).
    Lissitchkov TJ, Buevich E, Kuliczkowski K, Stasyshyn O, Cerqueira MH, Klukowska A, Joch C, Seifert W.
    Blood Coagul Fibrinolysis; 2017 Mar; 28(2):152-162. PubMed ID: 27203734
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study).
    Auerswald G, Djambas Khayat C, Stasyshyn O, Iosava G, Romashevskaya I, López MJ, Seifert W, Rogosch T.
    J Blood Med; 2020 Mar; 11():213-225. PubMed ID: 32607039
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical Efficacy and Safety of Fanhdi®, a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study.
    Jiménez-Yuste V, Alvarez-Román MT, Palomo Bravo Á, Galmes BJ, Nieto Hernández MDM, Benítez Hidalgo O, Marzo Alonso C, Pérez González NF, Coll J, Núñez R, Carrasco M, García Candel F, Gonzalez-Porras JR, Hernández García C, Varó Castro MJ, Mir R.
    Clin Appl Thromb Hemost; 2022 Mar; 28():10760296221074348. PubMed ID: 35108125
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Real-World Efficacy and Safety of Plasma-Derived Von Willebrand Factor-Containing Factor VIII Concentrates in Patients With Von Willebrand Disease in Italy.
    Federici AB, Santoro RC, Santoro C, Pieri L, Santi RM, Barillari G, Borchiellini A, Tosetto A, Zanon E, De Cristofaro R, Mairal E, Mir R.
    Clin Appl Thromb Hemost; 2024 Mar; 30():10760296241264541. PubMed ID: 39033425
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Continuous Infusion of Factor VIII and von Willebrand Factor in Surgery: Trials with pdFVIII LFB or pdVWF LFB in Patients with Bleeding Disorders.
    Windyga J, Guillet B, Rugeri L, Fournel A, Stefanska-Windyga E, Chamouard V, Pujol S, Henriet C, Bridey F, Négrier C.
    Thromb Haemost; 2022 Aug; 122(8):1304-1313. PubMed ID: 35642281
    [Abstract] [Full Text] [Related]

  • 14. Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results.
    Leebeek FWG, Peyvandi F, Escobar M, Tiede A, Castaman G, Wang M, Wynn T, Baptista J, Wang Y, Zhang J, Mellgård B, Özen G.
    Blood; 2022 Jul 14; 140(2):89-98. PubMed ID: 35439298
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of a VWF/FVIII concentrate (wilate® ) in inherited von Willebrand disease patients undergoing surgical procedures.
    Srivastava A, Serban M, Werner S, Schwartz BA, Kessler CM, Wonders Study Investigators.
    Haemophilia; 2017 Mar 14; 23(2):264-272. PubMed ID: 28026130
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery.
    Windyga J, von Depka-Prondzinski M, European Wilate® Study Group.
    Thromb Haemost; 2011 Jun 14; 105(6):1072-9. PubMed ID: 21437358
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness and safety of hFVIII/VWF concentrate (Voncento®) in patients with inherited von Willebrand disease requiring surgical procedures: the OPALE multicentre observational study.
    Rugeri L, d'Oiron R, Harroche A, Proulle V, Mourey G, De Raucourt E, Desprez D, Baikian NI, Petesch BP, Borel-Derlon A, Combe S, Frotscher B, Hassoun A, Catovic H, Bracquart D, Trossaërt M.
    Blood Transfus; 2021 Mar 14; 19(2):152-157. PubMed ID: 33263522
    [Abstract] [Full Text] [Related]

  • 20. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study.
    Dunkley S, Baker RI, Pidcock M, Price J, Seldon M, Smith M, Street A, Maher D, Barrese G, Stone C, Lloyd J.
    Haemophilia; 2010 Jul 01; 16(4):615-24. PubMed ID: 20331755
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.